Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2Q26

NU Skin cuts guidance as revenue and margins fall, with India launch delayed to 1H27.

What the company is saying

NU Skin Enterprises Inc. presents a narrative centered on operational discipline and long-term transformation, while acknowledging near-term headwinds. The company highlights $320.1M in revenue, $10.0M in adjusted net income, and $0.20 in adjusted EPS, but places emphasis on adjusted rather than GAAP results due to a $78.9M goodwill impairment and $167.5M deferred-tax valuation allowance. Management frames the Prysm iO rollout as the core growth engine, citing over 39,000 devices placed and a target of 50,000-60,000 by year-end. The announcement downplays the scale of revenue and margin declines, instead focusing on incremental improvements in core Nu Skin gross margin and a smaller year-over-year decline in sales leaders. The India launch is deferred to 1H27, attributed to ongoing work on sourcing, logistics, technology, and the affiliate model, but without quantifiable milestones. The tone is neutral and measured, with no promotional language or notable individual endorsements.

What the data suggests

Reported revenue of $320.1M reflects a clear year-over-year decline for both Nu Skin (down 15.5%) and Rhyz (down 25.0%). Adjusted net income stands at $10.0M, while adjusted EPS is $0.20, but GAAP EPS is sharply negative at $(5.14) due to significant non-cash charges. Core Nu Skin gross margin improved by 20 basis points to 77.7%, yet consolidated gross margin fell 60 basis points to 68.2%, and adjusted operating margin dropped 190 basis points to 6.1%. Sales leaders declined 9% year-over-year, a smaller drop than the previous quarter's 13%, while Mainland China sales leaders increased 2%. Management has reduced FY26 revenue guidance to $1.28B-$1.35B (from $1.35B-$1.50B) and adjusted EPS to $0.70-$0.90 (from $0.80-$1.20), signaling lower future expectations. The Prysm iO initiative is supported by device placement and scan numbers, but there is no direct link to financial improvement. Operational claims about India lack supporting data.

Analysis

The announcement is factual and measured, with no evidence of narrative inflation or exaggerated tone. Most claims are realised and supported by numerical data, including revenue, adjusted net income, EPS, and margin figures. The forward-looking statements (India launch timing, Prysm iO device targets) are presented as updates or revised guidance, not as promotional aspirations. The overall financial direction is negative, with declining revenue, margins, and reduced guidance, and these are disclosed transparently. There is no evidence of a large capital outlay paired with only long-dated, uncertain returns. The language is proportionate to the results, and no specific phrases overstate the company's progress.

Risk flags

• ●Sustained revenue and margin declines raise questions about the company's ability to stabilize its core business. Both Nu Skin and Rhyz posted double-digit revenue drops, and consolidated gross margin fell 60 basis points, indicating ongoing pressure.
• ●The India launch has been delayed to 1H27, with no quantifiable milestones or evidence of progress on sourcing, logistics, or technology integration. This introduces execution risk and uncertainty around the timing and scale of any contribution from this market.
• ●Heavy reliance on adjusted metrics obscures the impact of large non-cash charges, including a $78.9M goodwill impairment and a $167.5M deferred-tax valuation allowance. The sharp divergence between adjusted and GAAP EPS could mask underlying business challenges.
• ●Forward-looking claims for Prysm iO are based on device placement and scan counts, but there is no evidence these metrics translate to revenue or profit growth. Without clear financial linkage, the initiative's impact remains speculative.

Bottom line

NU Skin's latest update signals deteriorating fundamentals, with revenue, margins, and sales leaders all declining and management lowering both revenue and EPS guidance for FY26. The company's focus on adjusted results and operational initiatives like Prysm iO does not offset the lack of near-term financial improvement or the absence of quantifiable progress in new markets such as India. The India launch delay to 1H27 further pushes out any potential upside, while the gap between adjusted and GAAP earnings highlights underlying business stress. For investors, the announcement offers little evidence of a turnaround, and the narrative remains long on operational ambition but short on near-term results. The most important takeaway is that the pathway to recovery is both delayed and uncertain, with execution risks mounting and no clear catalyst for a financial rebound.

Announcement summary

(NYSE: NUS) NU Skin Enterprises Inc. reported revenue, adj NI, and adj EPS of $320.1M, $10.0M, and $0.20, respectively. GAAP EPS was $(5.14), primarily reflecting a $78.9M non-cash goodwill impairment and a $167.5M deferred-tax valuation allowance, both excluded from adjusted results. Core Nu Skin gross margin improved 20 bps y/y to 77.7%, while consolidated gross margin declined 60 bps to 68.2% and adjusted operating margin fell 190 bps to 6.1%. Nu Skin and Rhyz revenue declined 15.5% and 25.0% y/y, respectively. Management reduced FY26 revenue guidance to $1.28B-$1.35B from $1.35B-$1.50B and adjusted EPS to $0.70-$0.90 from $0.80-$1.20. India also moved to 1H27 from year-end 2026 as NUS refines local sourcing, logistics, technology integration, and the affiliate model. Prysm iO remains the central longer-term growth initiative, with more than 39,000 devices placed and 2.5M scans completed as NUS targets 50,000-60,000 devices by year-end.

Disagree with this article?